This section includes information and resources about Human Immunodeficiency Virus (HIV) for journalists: Boehringer Ingelheim press releases, background information, related press kits and a collection of images and videos.
Boehringer Ingelheim and Gilead sign license agreement for novel HIV non-catalytic integrase inhibitors
Viramune® (nevirapine) prolonged-release once-daily formulation for the treatment of HIV-1 infection receives approval in the EU- For non-US healthcare media
Viramune® (nevirapine) prolonged-release once-daily formulation for the treatment of HIV-1 infection receives CHMP recommendation for approval- For non-US healthcare media
U.S. FDA approves once-daily Viramune® XR™ tablet for use in combination with other antiretroviral agents for treatment of HIV-1 infection in adults- For non-U.S. medical media
HIV-1 patients with an undetectable viral load can switch to VIRAMUNE® regardless of their CD4 count- For medical media outside the US only
ARTEN Results 1/3
ARTEN Results 2/3
ARTEN Result 3/3
ARTEN Pre-Results 1/4
ARTEN Pre-Results 2/4
ARTEN Pre-Results 3/4
ARTEN Pre-Results 4/4
The human immunodeficiency virus (HIV), the causative agent of AIDS, is a retrovirus. It enters living cells and uses the host cell's replication machinery.
During HIV infection, millions of viral particles are present in the blood stream. They continuously infect cells of the immune system.
The battle between the viral infection and the cells of the immune system continues throughout the course of the infection.
Perinatal transmission of HIV from mother to baby is the major cause of HIV infections in children worldwide.
HIV is able to infect the central nervous system (CNS), including the brain. The CNS has been shown to be a major reservoir of virus.